SCHEMBL20577845

SCHEMBL20577845

CC(C)(C)OC(=O)Nc1ccc(F)c(NC(=O)c2cc(C#N)cc(C(F)(F)F)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.42
TEK Q02763 1/20 0.41
KDR P35968 1/20 0.41
EGLN2 Q96KS0 1/20 0.40
RORC P51449 1/20 0.40
POLB P06746 1/20 0.40
DDR1 Q08345 1/20 0.39
TMPRSS4 Q9NRS4 1/20 0.39
RHOC P08134 1/20 0.39
RHOA P61586 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20577956 0.90 RXFP1 (0.48) RXFP1KDRRORCPOLBRHOC
SCHEMBL20578026 0.88 KDR (0.51) RXFP1KDRRORCPOLBRHOC
SCHEMBL20578027 0.86 KDR (0.50) RXFP1KDRPOLBTMPRSS4
SCHEMBL20577765 0.86 KDR (0.47) RXFP1KDRRORCPOLBRHOC
SCHEMBL20578183 0.86 ACLY (0.47) RXFP1KDRPOLBDDR1TMPRSS4
SCHEMBL20577742 0.85 NOTUM (0.45) RXFP1RORCPOLBDDR1TMPRSS4
SCHEMBL29286680 0.83 KDR (0.40) RXFP1TEKKDRDDR1TMPRSS4
SCHEMBL20578112 0.82 KDR (0.49) RXFP1KDRPOLB
SCHEMBL29448812 0.81 ALDH1A1 (0.50) POLB
SCHEMBL29286676 0.81 ALDH1A1 (0.50) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3412670-B1 PYRIDINE DERIVATIVES INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE THEREOF SAMJIN PHARM CO LTD (KR) 2022-03-09 EP disclosed
CN-109071543-B Pyridine derivatives inhibiting RAF kinase and vascular endothelial growth factor receptor, process for their preparation, pharmaceutical compositions containing them and their use 三进制药株式会社 2021-07-16 CN disclosed
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2020-11-24 US disclosed
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2019-10-03 US disclosed
CN-109071543-A Inhibit the pyridine derivate of RAF kinases and vascular endothelial growth factor receptor, preparation method contains its medical composition and its use 三进制药株式会社 2018-12-21 CN disclosed
EP-3412670-A1 PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2018-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof BRAF, KDR, RAF1 RXFP1 186/4885TEK 14/4885KDR 2/4885
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof BRAF, KDR, RAF1 RXFP1 186/4885TEK 14/4885KDR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.